From Cannabis to Deltas To THCA to EPN: The Cannabinoid Truth

Euphorinol (EPN) Overview

Discover the newest breakthrough in hemp-derived cannabinoids. Known as the “Super Sativa”, euphorinol delivers euphoric clarity, uplifting energy, and clear-headed calm…without THC. With the launch of our Euphorinol Disposable Vapes, Hemp Remedies is proud to be one of the first companies to bring this innovation to market. Each vape is sleek, portable, and ready to use, making it the easiest way to experience the benefits of EPN.  

The Certificate of Analysis for Euphorinol (EPN) confirms a composition of 40.42% CBD and 28.50% CBG, with no detectable THC. Testing further verified product integrity, showing no presence of synthetic or Spice-type compounds.  View COA for EPN here

What is EPN or Euphorinol?

EPN (“Super Sativa”) is described as a newly discovered, semi-synthetic cannabinoid derived from hemp and marketed by Euphorinol. It is positioned as a non-THC, non-traditional analogue compound that delivers uplifting, Sativa-like effects. Unlike THC, THCP, or HHC, EPN is promoted as producing clear-headed euphoria without anxiety, paranoia, or sedation.  

EPN benefits and effects:

EPN is marketed as highly potent, with effective vape formulations using only 1.5–2% EPN content. Reported effects include euphoric uplift, mental clarity, consistent effects without tolerance buildup, and a medium onset (10–30 minutes) with 3–4 hours of duration. Promotional materials highlight that users can remain productive and socially engaged (“no couch-lock”) and that EPN may amplify the effects of other cannabinoids when blended.

How does EPN differ from THCA, Delta-8, Delta-9, and from traditional cannabinoids?

The company contrasts EPN with THC (impairing), THCP (tolerance-building), and HHC (associated with brain fog). EPN is positioned as a “controlled, predictable” alternative for both new and experienced users seeking Sativa-like stimulation.

Applications and market potential

EPN is being marketed in multiple product forms, including vape fluids, edibles/gummies, mouth strips, tinctures, and beverages. It is described as patent-protected with an available MSDS (under NDA) and promoted as a competitive advantage for early adopters.

EPN wholesale products and supply chain

Initial supply is limited to 10 kg over the first three weeks, with a planned tenfold increase in monthly availability. Orders require a 50% upfront deposit, with remaining payment due at shipment. Finished products (vapes, gummies, tinctures) and wholesale blends are sold under a volume-based pricing model. The company does not sell concentrated EPN directly, instead offering blends through its facility.

Why Should Smoke Shops Consider EPN?

Market Timing and Opportunity

With regulators tightening their stance on THCA and other hemp-derived cannabinoids, Euphorinol (EPN) is emerging as one of the few viable alternatives in the space. Early adoption gives retailers a chance to secure market share, influence consumer perception, and benefit from a first-mover advantage. Positioned as a distinct category shift, Euphorinol emphasizes potency, functional uplift, and commercial readiness.

Product Positioning

EPN, often described as a “Super Sativa,” is marketed as a semi-synthetic hemp-derived cannabinoid designed for clarity, focus, and a euphoric lift—without the heavy sedation or intoxication linked to traditional THC. Unlike conventional cannabis or THC analogs, it targets consumers seeking energy, creativity, and daytime functionality.

For shops already carrying CBD, HHC, or hemp-based products, EPN offers a compelling upsell and differentiator. Its low inclusion rates in vapes, tinctures, and edibles make it practical for blending without cutting into margins. The appeal lies in its reported ability to deliver mood elevation and mental clarity with minimal grogginess—potentially attracting a niche audience of professionals, creatives, and health-conscious users.

Considerations and Risks

Despite the upside, Euphorinol remains new and relatively untested. Retailers must weigh risks tied to regulatory ambiguity, limited safety data, and evolving consumer perception. Concerns have been raised about potency claims, synthetic origins, and the lack of long-term scientific validation. Careful due diligence is essential:

• Verify all third-party lab results and certificates of analysis.
• Ensure ingredient transparency from suppliers.
• Confirm compliance with state laws and retain verifiable documentation.

Failure to manage these factors could expose retailers to legal or reputational risks.

EPN: Should I Sell It?

Euphorinol (EPN) may represent a lucrative frontier for forward-thinking smoke shops and gas station operators. If backed by transparent testing and clear communication, it could serve consumers searching for an energizing, “weed-like” experience without traditional THC drawbacks. Success, however, will depend on careful positioning, rigorous compliance, and staying ahead of rapidly shifting hemp regulations.